theobromine has been researched along with Autoimmune Diabetes in 8 studies
Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)
theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human serum sickness is a syndrome characterized by fever, malaise, skin rashes, arthralgias, gastrointestinal disturbances, and lymphadenopathy." | 5.27 | Serum sickness associated with cefoxitin and pentoxifylline therapy. ( Gibson, K; Glynn, MJ; Hanson, VA; Panwalker, AP, 1986) |
| "Human serum sickness is a syndrome characterized by fever, malaise, skin rashes, arthralgias, gastrointestinal disturbances, and lymphadenopathy." | 1.27 | Serum sickness associated with cefoxitin and pentoxifylline therapy. ( Gibson, K; Glynn, MJ; Hanson, VA; Panwalker, AP, 1986) |
| "Pentoxifylline was used in the treatment of 90 patients with atherosclerosis-induced chronic peripheral arterial occlusive disease and diabetic vascular disorders in the lower extremities (clinical Fontaine Stages III and IV) for whom surgical reconstructive treatment was not indicated and who had shown inadequate response to previous therapy." | 1.27 | Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. ( Seige, K; Sternitzky, R, 1985) |
| "A long-term trial with oral pentoxifylline ("Trental" 400) in a dosage of 1200 mg per day was carried out in 70 diabetic patients with and without vascular afflictions." | 1.27 | Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. ( Ferrari, E; Solerte, SB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valentini, M | 1 |
| Sciannameo, F | 1 |
| Francucci, M | 1 |
| Tockner, M | 1 |
| Sassano, L | 1 |
| Allegra, A | 1 |
| Pozza, G | 1 |
| Cordaro, C | 1 |
| Carandente, O | 1 |
| Margonato, A | 1 |
| Roul, C | 2 |
| Juhan-Vague, I | 2 |
| Rahmani-Jourdheuil, D | 2 |
| Mishal, Z | 2 |
| Vague, P | 2 |
| Mourayre, Y | 1 |
| le Petit, J | 1 |
| Ferrari, E | 2 |
| Fioravanti, M | 1 |
| Patti, AL | 1 |
| Viola, C | 1 |
| Solerte, SB | 2 |
| Panwalker, AP | 1 |
| Gibson, K | 1 |
| Glynn, MJ | 1 |
| Hanson, VA | 1 |
| Sternitzky, R | 1 |
| Seige, K | 1 |
1 trial available for theobromine and Autoimmune Diabetes
| Article | Year |
|---|---|
[Erythrocyte filterability and treatment with pentoxifylline].
Topics: Diabetes Mellitus, Type 1; Diabetic Angiopathies; Erythrocytes; Humans; Middle Aged; Oxygen Consumpt | 1983 |
7 other studies available for theobromine and Autoimmune Diabetes
| Article | Year |
|---|---|
Study on relationship between erythrocyte filtration and other risk factors in diabetic angiopathy.
Topics: Diabetes Mellitus, Type 1; Diabetic Retinopathy; Erythrocytes; Female; Fibrinogen; Humans; Male; Pen | 1981 |
[The effect of pentoxifylline and propentofylline on the membrane fluidity of red blood cells in uncontrolled insulin-dependent (type 1) diabetic patients].
Topics: Diabetes Mellitus, Type 1; Diphenylhexatriene; Erythrocyte Membrane; Fluorescence Polarization; Huma | 1988 |
Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Erythrocyte Membrane; Fluorescence Polarization; Humans; Middle Ag | 1987 |
Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 1987 |
Serum sickness associated with cefoxitin and pentoxifylline therapy.
Topics: Cefoxitin; Diabetes Mellitus, Type 1; Drug Interactions; Humans; Male; Middle Aged; Pentoxifylline; | 1986 |
Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease.
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Diabetes Mellitus, Type 1; Diabetes Mell | 1985 |
Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopath | 1985 |